Background/Objectives: The aim of this retrospective study is to analyze the prevalence of adrenal masses in patients with different types of tumors who performed [18F]FDG PET/CT.Method: Eighty-eight patients who performed [18F]FDG PET/CT from 2019 to 2024 for oncologic purposes, with evidence of adrenal mass and different types of cancer, were retrospectively retrieved from our database. To assess the functionality of the adrenal lesions, ACTH, adrenal steroids, and a low-dose dexamethasone suppression test (DST-1 mg) was performed in the Endocrinology Unit. According to the results of DST-1 mg, the adrenal lesions were classified in cortisol-secreting lesions (CS) and non-secreting lesions (NS).Results: Adrenal masses were most prevalent in breast cancer (25/88, 28.4%), followed by kidney cancer (13/88, 14.8%), thyroid cancer (11/88, 12.5%), and the others. We report a global rate of 39.8% (34/88) cortisol-secreting amongst all adrenal lesions.Conclusions: Our study is the largest retrospective study available in the literature calculating the prevalence of adrenal lesions in several cancer patients. From our results there emerges a high prevalence of secreting lesions. Therefore, biochemical characterization of adrenal masses is crucial in oncological settings to address clinical and therapeutic management.
背景/目的：本回顾性研究旨在分析不同类型肿瘤患者在接受[18F]FDG PET/CT检查时肾上腺占位的患病率。方法：从我院数据库中回顾性收集2019年至2024年间因肿瘤诊疗目的接受[18F]FDG PET/CT检查、且存在肾上腺占位证据的88例不同类型癌症患者。为评估肾上腺病变功能，所有患者在内分泌科接受促肾上腺皮质激素、肾上腺类固醇激素检测及小剂量地塞米松抑制试验（DST-1 mg）。根据DST-1 mg结果，将肾上腺病变分为皮质醇分泌性病变（CS）与非分泌性病变（NS）。结果：肾上腺占位在乳腺癌患者中最为常见（25/88，28.4%），其次为肾癌（13/88，14.8%）、甲状腺癌（11/88，12.5%）及其他类型肿瘤。所有肾上腺病变中皮质醇分泌性病变总体占比达39.8%（34/88）。结论：本研究是文献中规模最大的回顾性研究，系统评估了多种癌症患者肾上腺病变的患病率。结果显示分泌性病变具有较高患病率。因此，在肿瘤临床诊疗中，对肾上腺占位进行生化特征分析对制定临床治疗策略至关重要。
肿瘤(癌症)患者之家